Articles tagged with Liver Cancer
Combined hepatocellular-cholangiocarcinoma is a rare and aggressive form of primary liver cancer that poses significant diagnostic and therapeutic challenges. The absence of standardized treatment guidelines limits effective management, emphasizing the need for thorough pathological evaluation and multidisciplinary management.
A study published in JAMA Network Open found that high consumption of sugar-sweetened beverages was linked to an increased risk of liver cancer. In contrast, artificially sweetened beverage intake showed no significant association with liver cancer risk.
Researchers at UMass Amherst have designed a new therapy that combines engineered Salmonella bacteria with oncolytic viruses to target liver and pancreatic cancer. The treatment showed promising results in animal models, leading to significant tumor reduction and improved survival rates.
UCLA researchers are developing an AI-enhanced imaging platform to improve yttrium-90 radioembolization planning for patients with liver cancer. The new approach uses dynamic contrast-enhanced MRI scans to better characterize tumor blood flow and predict microsphere distribution.
The study found high-risk associations between alcohol use and all ten cancers examined, with risk increasing progressively as intake rose. Low-to-moderate drinking was associated with lower disease risk for type 2 diabetes, Alzheimer's disease, ischemic heart disease, and stroke.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
A phase 2 clinical trial found that 65% of patients receiving avatrombopag met key treatment goals, compared to 17% of those receiving placebo treatment. The oral medication has been shown to be effective in maintaining platelet counts needed to continue chemotherapy as scheduled.
Researchers at the Sylvester Comprehensive Cancer Center presented several studies at ASCO 2026 exploring new treatment options for patients with advanced gastrointestinal stromal tumors (GISTs) and melanoma. These include velzatinib, a targeted therapy for GIST patients, and PRAME-directed T-cell receptor therapies for synovial sarcoma.
Researchers found that restoring a young microbiome can reverse features of aging in the liver, including inflammation and DNA damage. The study suggests that a healthy gut microbiome plays a key role in preventing liver cancer.
Immune checkpoint inhibitors can cause immune-related hepatotoxicity, which is associated with female sex, younger age, Asian ethnicity, chronic liver disease, specific cancers, dual ICI therapy, and concurrent hepatotoxic drugs. Promising biomarkers include blood cell counts, CRP, autoantibodies, cytokines, SNPs, HLA types, and gut mi...
Researchers developed a cancer assessment tool that can identify high-risk patients and specific cell populations linked to their risk. The tool, called scSurvival, predicts survival outcomes more accurately than traditional methods by analyzing single-cell data at cellular resolution.
Researchers developed an AI model called Path-IO that uses machine learning to predict responses to immunotherapy for patients with metastatic non-small cell lung cancer. The model accurately stratified patients into high-risk and low-risk groups, with patients in the high-risk group having double the risk of death or disease progression.
The study provides a roadmap for understanding and treating liver cancer by identifying key biological processes that enable tumors to grow and spread. It highlights the potential for precision medicine approaches, including immunotherapy and targeted therapies, to improve outcomes for patients with liver cancer.
The study reveals that metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as a major contributor to liver cancer worldwide and in China. Researchers call for integrated global prevention and early detection strategies to address this growing burden.
The Mount Sinai Hospital has pioneered a new minimally invasive liver cancer treatment method that allows doctors to treat patients on more days of the week, improving access and reducing wait times. This breakthrough innovation, called TheraSphere Y-90 Any Day Dosing, enables flexible scheduling and seamless care coordination.
A study published in Nature Health reveals a strong link between pesticide exposure and the risk of developing certain cancers. The research shows that pesticide exposure increases the risk of cancer by 150% in areas with high levels of pollution, and highlights early biological effects before cancer develops.
A new genetic 'roadmap' provides a navigational framework for more precise diagnosis and treatment of intrahepatic cholangiocarcinoma. The framework identifies five molecular subtypes, each associated with distinct therapeutic vulnerabilities, enabling targeted treatment strategies.
Researchers found that the three-drug combination increased autophagosome formation and autophagic flux in uveal melanoma cells, killing them via enhanced autophagy. The study suggests a potential therapeutic approach for treating metastatic uveal melanoma, particularly in liver-targeted disease.
The BiliSeq test detected approximately 82% of bile duct cancers, compared to 44% with pathology alone, and increased cancer detection to nearly 90% when combined with pathology. This improved accuracy enables physicians to provide more personalized medicine and treatment options for patients.
Researchers developed a machine learning model that analyzes patient demographics, electronic health record data, and blood test results to predict hepatocellular carcinoma (HCC) risk. The model achieved high accuracy and outperformed existing liver cancer risk prediction models, offering potential for widespread use in resource-limite...
Researchers from Institute of Science Tokyo reveal the SPP1–CD44–Hedgehog signaling pathway as a key driver of fibrosis in liver tumors, hinting at its potential as a therapeutic target. The study provides valuable insights into how liver tumors actively shape their surroundings, driving the onset and progression of fibrosis.
A positive feedback loop between UBE2V1 and HIF-1α drives HCC progression by facilitating tumor growth and metastasis. UBE2V1 promotes HCC progression by competing with HIF-1α for VHL protein binding, leading to sustained HIF-1α stabilization.
Women with cardiometabolic risk factors such as type 2 diabetes and high waist circumference face a higher risk of liver fibrosis, with rates increasing 11-fold and 2.8-fold compared to men. The study highlights the importance of managing these risk factors for liver health beyond heart disease prevention.
Researchers found that quantifiable HBV RNA levels are associated with a significantly higher risk of HCC, independent of traditional risk factors. Chronic hepatitis B patients with concurrent liver dysfunction should be intensified under surveillance for HCC.
A study from The University of Osaka reveals a molecular pathway connecting liver congestion to liver fibrosis, portal hypertension, and liver tumorigenesis. Researchers identified increased activity of YAP and CTGF in liver sinusoidal endothelial cells as key molecules involved in this signaling pathway.
Researchers create detailed 3D reconstructions of human liver tissue, comparing healthy and cirrhotic livers, showing dysregulation of metabolite transport, reduced specialized cells, and disruption of vascular networks. The study highlights the importance of understanding organ structure for bioprinting artificial organs.
A study by RIKEN researchers identifies a MYCN-driven biomarker that predicts the risk of liver cancer. The biomarker, known as the MYCN niche score, uses machine learning to analyze gene expression patterns and indicates whether a tumor-free liver is at high risk for developing tumors.
Researchers at PolyU have identified a key driver of tumour growth in liver cancer and developed a monoclonal antibody that neutralises this protein. The antibody inhibits the growth and proliferation of FABP4-driven cancer stem cells, enhancing immune cell activity.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
Researchers uncover a hypoxia–m⁶A–Gal-1 regulatory axis that fuels HCC progression by stabilizing Galectin-1 (Gal-1) mRNA, promoting malignant phenotypes. Functional experiments confirmed Gal-1's role in enhancing HCC cell proliferation, migration, invasion, and EMT-driven phenotypic plasticity.
Ochsner MD Anderson is offering histotripsy, a revolutionary non-invasive treatment for liver tumors, approved by the FDA in 2023. The procedure uses ultrasound energy to destroy liver tumors in a single outpatient procedure.
The American Cancer Society's new 'Cancer Statistics, 2026' report reveals a historic milestone: US cancer survivorship has reached a record 70%, driven by major gains in cancers once considered difficult to treat. However, the report also highlights persistent disparities, concerning increases in cancer among women and younger adults.
Researchers found that blocking Caspase-2 enzyme in mice increased chronic liver damage and cancer risk as they aged. The study highlights the need for caution when targeting this pathway to treat fatty liver disease.
A new rapid test for hepatitis C could identify more patients who can be cured if insurers increase reimbursement to cover the test's high cost. The test's point-of-care feature makes it ideal for early screening and treatment in clinics and emergency rooms.
A new MIT study shows that high-fat diets cause liver cells to revert to an immature state, making them more susceptible to cancer-causing mutations. This reversion is driven by genes that help the cells survive stressful conditions, but ultimately increases their likelihood of becoming cancerous.
UT Health San Antonio received $3 million in CPRIT grants to expand access to preventive salpingectomy, test novel methods to prevent liver cancer, and advance treatment for therapy-resistant metastatic breast cancer. These projects aim to improve cancer prevention, diagnosis, and treatment in South Texas.
Scientists identify targeting B-cells as a promising strategy to improve liver cancer immunotherapy. Researchers found that tumor-associated B-cells suppress T-cell activity, allowing cancer cells to escape immune attacks.
Research from Florida Atlantic University strengthens evidence that alcohol consumption increases cancer risk, particularly for breast, colorectal, and liver cancers. Higher intake and specific groups, such as African Americans and those with obesity or diabetes, are found to be more vulnerable to the risks.
A national survey of adults found that three-quarters support vaccinating newborns against hepatitis B, but Republicans are less likely to recommend the vaccine. The survey also found that most respondents believe the vaccine protects against liver disease, and there is little evidence justifying delaying vaccination.
A recent study by UCLA Health investigators found that mental health conditions significantly raise the likelihood of developing liver cancer among US veterans living with cirrhosis and hepatitis C. The study suggests that these disorders limit access to hepatitis C care, reducing the chance of a cure.
Researchers found that FOLFIRINOX improved progression-free and overall survival in patients with advanced biliary tract cancer. The treatment may offer a benefit as a second-line option after first-line chemotherapy failure, but toxicity remains a concern.
A novel liver cancer vaccine has achieved responses in a rare disease affecting children and young adults, with 75% of patients experiencing disease control. Three patients are now believed to be cancer-free after receiving the therapy, including a 13-year-old patient who achieved a nearly complete response.
The institute has opened its first specialized angiography-CT suite, integrating two forms of imaging equipment in one dedicated space. This allows interventional radiologists to perform both angiography and CT scans on the same day, reducing travel burdens for patients and improving treatment outcomes.
A new study in the Journal of Hepatology shows liver transplantation from MAiD donors yields similar survival rates as standard donation after circulatory death. This practice can significantly expand the donor pool, leading to more organs available for transplant and potentially saving thousands of lives.
Researchers identified a significant association between perfluoroheptanoic acid (PFHpA) exposure and metabolic dysfunction-associated steatotic liver disease (MASLD) in adolescents. The study used advanced models to reveal PFHpA's role in disrupting biological pathways, leading to liver damage and inflammation.
Glypican-3 is a key driver of hepatocellular carcinoma progression, facilitating metastasis and tumor microenvironment remodeling. Immunotherapy targeting GPC3 has shown preliminary safety and antitumor activity in clinical trials, with ongoing research focusing on optimized patient selection and disease monitoring.
Researchers have discovered myeloid cells in children's liver tumors that could be activated for treatment. This discovery provides new avenues for immunotherapy in childhood liver cancer.
A simple blood analysis can predict the risk of developing severe liver disease, enabling earlier detection and potentially improving treatment outcomes. The CORE model, developed by Karolinska Institutet researchers, is based on three routine blood tests and has been shown to be highly accurate in predicting liver disease risk.
The University of Cincinnati Cancer Center researchers are presenting several studies on radiation oncology, including the evaluation of efficacy and safety of proton re-irradiation in head and neck cancers, significant variation in oropharyngeal cancer treatment approaches, and severe toxicity rare following liver cancer ablative radi...
Researchers have identified CNNM4 as overexpressed in cholangiocarcinoma and found that inhibiting it, combined with GalNAc siRNA technology, can slow tumor growth and increase sensitivity to treatment. This approach could lead to personalized therapies for patients with limited treatment options.
DDX17 promotes HCC metastasis via the β-catenin/TCF4 pathway, inducing EMT and enhancing migration/invasion. The β-catenin/TCF4/DDX17 feedback loop is essential for HCC dissemination.
Researchers found that four common PFAS triggered fat buildup and cancer-related changes, with effects differing by sex. Liver cells from male and female donors responded differently to PFAS exposure.
Researchers have created a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents. This innovative platform replicates the microenvironment of liver tumors, providing unprecedented insight into how tumors respond to embolization.
Researchers at the University of Mississippi have developed a new method to deliver cancer therapies directly to triple-negative breast cancer cells. The sugar-coated nanoparticles effectively target this aggressive cancer, which affects young women and disproportionately impacts Black women. The discovery holds promise for treating no...
A new study found that a cell-based vaccine using dendritic cells can improve progression-free survival time for patients with intermediate-stage primary liver cancer. The ImmunoTACE trial showed an average of 18 months of tumor progression compared to 10 months in the control group.
The Lancet commission emphasizes the need for concrete goals to reduce hepatocellular carcinoma's growing disease burden. The authors propose a 2% annual reduction in age-standardized incidence rates and recommend evidence-based strategies to tackle viral hepatitis, alcohol consumption, environmental risk factors, and disparities in he...
Three in five liver cancer cases can be prevented by reducing viral hepatitis, alcohol consumption, and metabolic dysfunction-associated steatotic liver disease. The Lancet Commission estimates that if countries can reduce liver cancer incidence by 2-5% annually by 2050, it could prevent 9-17 million new cases and save 8-15 million lives.
Researchers have discovered a promising new approach to suppress the growth of aggressive cancers by targeting minor splicing, a specialized molecular process. By blocking minor splicing, cancer cells accumulate DNA damage and trigger cell death, while healthy cells remain largely unaffected.
A recent national study reveals complex patterns of burden and survival trends for digestive system malignancies (DSMTs) in China. Despite progress in reducing mortality from some cancers, the overall impact remains significant, with notable disparities across demographic and geographic lines.